Trials / Withdrawn
WithdrawnNCT01451450
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
A Phase II, Randomized, Double Blind, Placebo-controlled, Parallel Design, Dose Ranging, Multi-center Trial of Four Levels of Exposure of QGE031 s.c. for 16 Weeks in Subjects Aged 18-50 Years of Age With Peanut Allergy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QGE031 | QGE031 liquid for subcutaneous injection. |
| DRUG | Placebo | Placebo liquid for subcutaneous injection. |
Timeline
- First posted
- 2011-10-13
- Last updated
- 2012-07-23
Source: ClinicalTrials.gov record NCT01451450. Inclusion in this directory is not an endorsement.